MONTRÉAL, 15 June, 2023 – CQDM – biopharmaceutical research consortium – is proud to announce the arrival of Carl Baillargeon within its team as Chief communications and marketing officer. Carl Baillargeon is well known for his role as an Ambassador for life sciences, health technologies and innovation. For the past 20 years, he has consolidated…
MONTRÉAL, June 7, 2023 – Developing new generations of immunotherapies to treat currently incurable pediatric leukemia is the mission of Neomabs Biotechnologies, a new Montreal-based biotechnology company specializing in the discovery and development of innovative oncology therapies. The creation of Neomabs, the result of a strategic and innovative partnership between key players in the life…
Boston, Massachusetts – June 5, 2023 – CQDM is delighted, at BIO2023, in the presence of Minister Fitzgibbon, Quebec’s Minister of the Economy, Innovation and Energy (MEIE) to announce that Merck Canada, has renewed its commitment to CQDM with $3.0M in funding to support the development of innovative technologies in biopharmaceutical research. The innovative research and…
BOSTON, June 5, 2023 – Pierre Fitzgibbon, Quebec Minister of the Economy, Innovation and Energy, Minister responsible for Regional Economic Development and Minister responsible for the Metropolis and the Montreal Region, today announced financial assistance totalling nearly $1.96 million for four biopharmaceutical R&D projects under CQDM’s SynergiQc program. CQDM is proud to contribute to the…
Montreal, May 25, 2023 – Under BIOTECanada’s editorial direction, Insights Magazine is a goldmine of information about the global challenges and advancement of innovation in the biotech sector across Canada. In its most recent edition (page 78), our Director of Scientific Affairs, Fanny Guimont-Desrochers presents how collaborative R&D is a catalyst for innovation. She also highlights…
MONTREAL, April 18, 2023 – CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat several disabling pathologies such as chronic pulmonary obstruction and cystic fibrosis. CQDM is providing a grant of $201,512, made possible by the Ministère de l’Économie…
Over the past decade, a growing number of organizations in the research and innovation ecosystem have chosen to prioritize the integration of equity1, diversity2, and inclusion3 (EDI) into their activities. Why? The benefits of EDI initiatives are increasingly being documented and recognized at the societal, sectoral, organizational, and individual levels. What are the benefits for…
Kuldeep Neote MONTREAL, March 24, 2023 – CQDM is proud to announce the appointment of Kuldeep Neote as a member of its Scientific Advisory Board (SAB). The SAB is a key committee of CQDM as it provides strategic orientations in biopharmaceutical innovation and oversees the selection and monitoring of projects funded by CQDM. Kuldeep Neote…
ABOUT CQDM Since its inception, CQDM has raised more than $275 million to fund the development of 150 + drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and…
ABOUT CQDM Since its inception, CQDM has raised more than $275 million to fund the development of 150 + drugs addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and…